ロード中...
Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy—Real-World Clinical Impressions and Comparative Review of the Literature
Background: The introduction of checkpoint inhibitors is a long-awaited new option for a urothelial cancer with a poor prognosis. Apart from clinical studies, the data on real world experience is scarce. Methods: Patients for monotherapy with either Atezolizumab, Nivolumab or Pembrolizumab after che...
保存先:
| 出版年: | Front Oncol |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2020
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7253725/ https://ncbi.nlm.nih.gov/pubmed/32528889 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.00808 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|